After years in neurosurgery, here’s my take. Ozempic, Wegovy, and Mounjaro (GLP-1–based medications) are not cosmetic drugs. They target metabolic disease — and metabolic disease directly impacts the brain. What high-quality trials show: • SELECT (NEJM, 2023): Semaglutide reduced major cardiovascular events in overweight/obese adults without diabetes. • SUSTAIN-6 (NEJM, 2016): Semaglutide reduced stroke risk in patients with type 2 diabetes. • SURPASS program (2021–2023): Tirzepatide produced su
0:06
After years in neurosurgery, here’s my take. Ozempic, Wegovy, and Mounjaro (GLP-1–based medications) are not cosmetic drugs. They target metabolic disease — and metabolic disease directly impacts the brain. What high-quality trials show: • SELECT (NEJM, 2023): Semaglutide reduced major cardiovascular events in overweight/obese adults without diabetes. • SUSTAIN-6 (NEJM, 2016): Semaglutide reduced stroke risk in patients with type 2 diabetes. • SURPASS program (2021–2023): Tirzepatide produced su
1.7M views3 months ago
TikTokjagannathanneurosurgery
See more
Static thumbnail place holder